Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.

Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.

It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.

It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.

A method of extracting cannabidiol from hemp. The method may include the following steps: performing grinding and drying on an extraction part of the hemp to obtain crude drug powder; extracting the crude drug powder with 30-100% (V/V) ethanol to obtain an extracting solution; concentrating the extracting solution to obtain an extractum; performing water precipitation on the extractum to remove impurities, thereby obtaining a water precipitation solution; centrifuging the water precipitation solution, and adding 10-100% (V/V) ethanol to dissolve the obtained precipitate, thereby obtaining a precipitate alcohol solution; performing column chromatography on the precipitate alcohol solution; concentrating the eluate obtained by elution after column chromatography, and adding ethanol for supersaturation and dissolution to obtain a crystal; adding purified water or ethanol to wash the crystal, thereby obtaining a primary product; and uniformly mixing the primary product with purified water, and drying to obtain the cannabidiol.

A method of extracting cannabidiol from hemp. The method may include the following steps: performing grinding and drying on an extraction part of the hemp to obtain crude drug powder; extracting the crude drug powder with 30-100% (V/V) ethanol to obtain an extracting solution; concentrating the extracting solution to obtain an extractum; performing water precipitation on the extractum to remove impurities, thereby obtaining a water precipitation solution; centrifuging the water precipitation solution, and adding 10-100% (V/V) ethanol to dissolve the obtained precipitate, thereby obtaining a precipitate alcohol solution; performing column chromatography on the precipitate alcohol solution; concentrating the eluate obtained by elution after column chromatography, and adding ethanol for supersaturation and dissolution to obtain a crystal; adding purified water or ethanol to wash the crystal, thereby obtaining a primary product; and uniformly mixing the primary product with purified water, and drying to obtain the cannabidiol.

This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.

It discloses a compound of formula I that inhibits the activities of numerous of protein kinases involving the signaling of inflammatory cytokines, therefore, the compound can be used for treating cancers, autoimmune diseases and inflammatory diseases.